A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid) In Patients With Mantle-Cell Lymphoma.

Trial Profile

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid) In Patients With Mantle-Cell Lymphoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms RENEW
  • Most Recent Events

    • 06 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by German Clinical Trials Register.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003817).
    • 28 Apr 2012 Planned number of patients changed from 382 to 450 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top